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Obsessive-compulsive disorder is a severe psychiatric disorder linked to abnormalities in
glutamate signaling and the cortico-striatal circuit. We sequenced coding and regulatory
elements for 608 genes potentially involved in obsessive-compulsive disorder in human, dog,
and mouse. Using a new method that prioritizes likely functional variants, we compared 592
cases to 560 controls and found four strongly associated genes, validated in a larger cohort.
NRXN1 and HTR2A are enriched for coding variants altering postsynaptic protein-binding
domains. CTTNBP2 (synapse maintenance) and REEP3 (vesicle trafﬁcking) are enriched for
regulatory variants, of which at least six (35%) alter transcription factor-DNA binding in
neuroblastoma cells. NRXN1 achieves genome-wide signiﬁcance (p= 6.37 × 10−11) when we
include 33,370 population-matched controls. Our ﬁndings suggest synaptic adhesion as a key
component in compulsive behaviors, and show that targeted sequencing plus functional
annotation can identify potentially causative variants, even when genomic data are limited.
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Obsessive-compulsive disorder (OCD) is a highly heritable(h2= 0.27–0.65)1, debilitating neuropsychiatric disordercharacterized by intrusive thoughts and time-consuming
repetitive behaviors. Over 80 million people worldwide are esti-
mated to suffer from OCD, and most do not ﬁnd relief with
available therapeutics1, underscoring the urgency to better
understand the underlying biology. Genome-wide association
studies (GWAS) implicate glutamate signaling and synaptic
proteins2, 3, but speciﬁc genes and variants have not been vali-
dated. Isolating and characterizing such genes are important for
understanding the biology and developing treatments for this
devastating disease.
In mouse, genetically engineered lines have causally implicated
the cortico-striatal neural pathway in compulsive behavior. Mice
with a deletion of Sapap3 exhibit self-mutilating compulsive
grooming and dysfunctional cortico-striatal synaptic transmis-
sion, with abnormally high activity of medium spiny neurons
(MSNs) in the striatum. Resulting compulsive grooming is
ameliorated by selective serotonin reuptake inhibitor (SSRI), a
ﬁrst-line medication for OCD4. Similarly, chronic optogenetic
stimulation of the cortico-striatal pathway in normal mice leads
to compulsive grooming accompanied by sustained increases in
MSN activity5. Thus, excessive striatal activity, likely due to
diminished inhibitory drive in MSN microcircuitry, is a key
component of compulsive grooming. The brain region disrupted
in this mouse model is also implicated by imaging studies in
human OCD6.
Pet dogs are a natural model for OCD amenable to genome-
wide mapping due to their unique population structure7. Canine
compulsive disorder (canine CD) closely parallels OCD, with
equivalent clinical metrics, including compulsive extensions of
normal behaviors, typical onset at early social maturity, roughly a
50% rate of response to SSRIs, high heritability, and polygenic
architecture8. Through GWAS and targeted sequencing in dog
breeds with exceptionally high rates of canine CD, we associated
genes involved in synaptic functioning and adhesion with CD,
including neural cadherin (CDH2), catenin alpha2 (CTNNA2),
ataxin-1 (ATXN1), and plasma glutamate carboxypeptidase
(PGCP)8, 9.
Human genetic studies of related disorders, such as autism
spectrum disorders (ASD), suggest additional genes. Both ASD
and OCD are characterized by repetitive behaviors, and high
comorbidity suggests a shared genetic basis6. Genome-wide stu-
dies searching for de novo and inherited risk variants have con-
ﬁdently associated hundreds of genes with ASD; this set may be
enriched for genes involved in OCD10.
Focusing on genes implicated by model organisms and related
disorders could ﬁnd variants underlying OCD risk, even with
smaller sample sizes. Researchers, particularly in psychiatric
genetics, are wary of “candidate gene” approaches, which often
failed to replicate11. Closer examination of past studies suggests
this approach is powerful and reliable when the set of genes tested
is large, and the association is driven by rare variation11. A study
testing 2000 candidate genes for association with diabetic reti-
nopathy identiﬁed 25 genes, at least 11 of which achieved
genome-wide signiﬁcance in a GWAS of type 2 diabetes, a related
disorder12, 13. A targeted-sequencing study of ASD, with 78 genes,
identiﬁed four genes with recurrent, rare deleterious mutations;
these four genes are also implicated by whole-exome sequencing
studies14. Candidate gene studies also replicated associations to
rare variants in APP, PSEN1, and PSEN2 for Alzheimer’s dis-
ease15, PCSK9 for low-density lipoprotein–cholesterol level16, and
copy-number variants for autism and schizophrenia10.
Detecting associations driven by rare variants requires
sequencing data, which captures nearly all variants. Although
whole-genome sequencing studies of complex diseases are still
prohibitively expensive, it is feasible to target a subset of the
genome. Sequencing also facilitates identiﬁcation of causal var-
iants, accelerating discovery of new therapeutic avenues17, 18. For
example, ﬁnding functional, rare variants in PCSK9 led to new
therapies for hypercholesterolemia19. One approach is to target
predominantly coding regions (whole-exome sequencing).
Although successful in ﬁnding causal variants for rare diseases20,
this approach misses the majority of disease-associated variants
predicted to be regulatory21. A targeted-sequencing approach that
captures both the regulatory and coding variation of a large set of
candidate genes offers many advantages of whole-genome
sequencing, and is feasible when cohort size and resources are
limited.
Here we report a new strategy that overcomes limitations of
less comprehensive candidate gene studies and exome-only
approaches, and identiﬁes functional variants associated with
increased risk of OCD. We start by compiling a large set of 608
genes (~3% of human genes) using studies of compulsive beha-
vior in dogs and mice, and studies of ASD and OCD in humans.
By focusing on this subset of genes, targeting both coding and
regulatory regions, and applying a new statistical method that
incorporates regulatory and evolutionary information, we identify
four associated genes, including NRXN1, the ﬁrst genome-wide-
signiﬁcant association reported for OCD.
Results
Targeted-sequencing design. We compiled a list of 608 genes
using three strategies (65 were implicated more than once)
(Supplementary Table 1 and Supplementary Methods):
(1) 263 “model-organism genes”, including 56 genes asso-
ciated in canine CD GWAS and 222 genes implicated in
murine-compulsive grooming.
(2) 196 “ASD genes” from SFARI database (https://gene.sfari.
org/) as of 2009.
(3) 216 “human candidate genes” from small-scale OCD
candidate gene studies (56 genes), family-based linkage
studies of OCD (91 genes), and by other neuropsychiatric
disorders (69 genes).
We targeted coding regions and 82,723 evolutionarily con-
strained elements in and around these genes, totaling 13.2 Mb
(58 bp–16 kb size range, median size 237 bp), 34% noncoding22.
Variant detection. We sequenced 592 European ancestry DSM-
IV OCD cases and 560 ancestry-matched controls using pooled
sequencing, with 16 samples per bar-coded pool (37 “case” pools;
35 “control” pools). Overall, 95% of target regions were
sequenced at >30× read depth per pool (median 112×; ~7× per
individual; Supplementary Fig. 1), sufﬁcient to identify variants
occurring in just one individual, assuming 0.5–1% per base
machine error rate.
We called 124,541 single nucleotide polymorphisms (SNPs)
using Syzygy (84,216)17 and SNVer (81,829)23. For primary
analyses, we focused on 41,504 “high-conﬁdence” SNPs detected
by both, with highly correlated allele frequencies (AF) (Pearson’s
ρ= 0.999, p< 2.2 × 10−16; Supplementary Fig. 2). We see no
signiﬁcant difference between case and control pools, indicating
no bias in variant detection.
Variant annotation. We used three annotations shown to be
enriched for disease-associated variation to identify likely func-
tional variants in our targeted regions: coding, evolutionary
conserved, and/or DNase1 hypersensitivity site (DHS)21, 24–27.
We annotated 67% (27,626) of high-conﬁdence variants, with
16% coding (49% of those were non-synonymous), 36% DHS,
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and 80% evolutionary conserved or divergent (Fig. 1a). We
measured evolutionary constraint using mammalian GERP++
scores27; scores >2 were “conserved” and scores <–2 were
“divergent”.
Gene-based burden analysis. To identify genes with a signiﬁcant
load of non-reference alleles in OCD cases, relative to controls, we
developed PolyStrat, a one-sided gene-based burden test that
controls for gene length (Supplementary Fig. 3a) and incorporates
variant annotation. We used four variant categories: (i) all
(Overall), (ii) coding (Exon), (iii) regulatory (variants in DHS),
and (iv) rare (1000 Genomes Project28 AF< 0.01). Each category
is further stratiﬁed by evolutionary status: (i) all detected variants;
(ii) slow-evolving conserved (Cons); (iii) fast-evolving divergent
(Div); and (iv) evolutionary (Evo). “Evo” is the subset of “all”
variants annotated as either “conserved” or “divergent”. In total,
27,867 18,72719,498 23,018
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Fig. 1 PolyStrat analysis of pooled-targeted-sequencing data. a Venn diagrams showing the number of SNPs annotated as functional and/or conserved by
PolyStrat. Each of the four dashed circles represents the 41,504 total high-conﬁdence SNPs detected. Within each circle, SNPs are stratiﬁed by their
annotations. Each colorful interior circle represents SNPs annotated as exonic (blue), regulatory (green), conserved (red), or diverged (gray) bases. SNPs with
multiple annotations are represented by circle overlaps, and SNPs without any of the included annotations are within the white space of the dashed outer
circle. b PolyStrat p-values for 608 genes (circles) stratiﬁed by the 16 (12 shown) annotation categories tested show that just ﬁve genes (NRXN1, HTR2A,
LIPH, CTTNBP2, and REEP3) have p-values below the experiment-wide signiﬁcance threshold after correction for multiple testing (red dashed line). Two
moderately associated, OCD-relevant genes discussed in the text are also noted (STRN and CACNA1C). “Evo” (=evolutionary) are SNPs either conserved
(“Cons”) or divergent (“Div”). The vast majority of genes tested fail to exceed the signiﬁcance threshold, with the median p-value for each category shown
as a dark black line separating two boxes representing the 25–75% quantile. Notch in boxes shows the 95% conﬁdence interval around median.
c p-values for the ﬁve genes robustly implicated in animal models of OCD are signiﬁcantly lower than p-values for the rest of the genes in our sequencing
set (603 genes), and this difference increases when just rare variants are tested. The solid horizontal line shows median p-value, the boxed area the 25–75%
quantiles, and the vertical black lines extend from the minimum to maximum p-values observed. AF, allele frequency
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PolyStrat considers 16 groups stratiﬁed by predicted function and
evolutionary conservation.
PolyStrat p-values are corrected for multiple testing empirically
using a permutation-based method that accurately measures
experiment-wide statistical signiﬁcance across correlated gene-
based tests, while controlling for type 1 errors (Supplementary
Methods). For most variant categories, quantile–quantile plots
revealed good correspondence between observed values and the
empirical null, with a small number of genes exceeding the
expected distribution in a subset of the burden tests (Supple-
mentary Figs. 3b and 4).
Five of the 608 sequenced genes (0.82%) show signiﬁcant
burdens of variants in OCD patients (Table 1; Fig. 1b), including
two with excess coding variants (NRXN1 and HTR2A) and two
with excess regulatory variants (CTTNBP2 and REEP3) (Fig. 2).
REEP3 is the only gene with excess divergent (potentially fast
evolving) variants. No genes had a signiﬁcant burden of rare
variants (Supplementary Fig. 4).
We validated the 46 SNPs contributing to signiﬁcant gene-
burden tests (7 in LIPH, 13 in NRXN1, 4 in HTR2A, 15 in
CTTNBP2, and 7 in REEP3) by individual genotyping of 571
OCD and 555 control samples (98% of the cohort). Nine variants
failed Sequenom assay design or had low genotyping rates. For
the remaining 37, the genotyping and pooled-sequencing
frequencies are nearly perfectly correlated (Pearson’s ρ= 0.999,
p< 2.2 × 10−16; Supplementary Fig. 5; Supplementary Data 1).
We conﬁrmed that our signiﬁcant gene-burden test ﬁndings
are not driven by population structure (Supplementary Methods)
or linkage disequilibrium (LD), with one notable exception. We
measured pairwise r2 between SNPs contributing to the burden
test in our top ﬁve genes, and found strong LD (r2> 0.8) between
one pair, in LIPH. There was no strong LD in NRXN1, HTR2A,
CTTNBP2, and REEP3.
Genes included from model-organism studies (263 genes) and
larger ASD studies (196 genes) were signiﬁcantly more associated
than genes from human candidate gene studies (216 genes)
Table 1 Five genes with signiﬁcant variant burden in OCD cases in pooled sequencing data
Genes Description Total SNPs in
PolyStrat
Case-abundant SNPs in
PolyStrat
PolyStrat category (one-sided
burden P)
LIPHa Lysophosphatidic acid production61 7 6 (86%) Overall (4 × 10−4)
NRXN1 Encodes a synapse adhesion molecule 8 8 (100%) Exon-Cons (2 × 10−4)
13 10 (77%) Exon-All (2 × 10−4)
12 10 (83%) Exon-Evo (3 × 10−4)
HTR2A Indirect target for SSRI medications50 4 4 (100%) Exon-Cons (9 × 10−4)
CTTNBP2 Modulates postsynaptic cortactin62 5 3 (60%) DHS-Cons (5 × 10−4)
15 8 (53%) DHS-All (9 × 10−4)
REEP3 Regulates cellular vesicle trafﬁcking 3 3 (100%) Overall-Div (1 × 10−4)
4 4 (100%) DHS-Evo (6 × 10−4)
6 5 (83%) DHS-All (8 × 10−4)
aSigniﬁcance of association possibly inﬂated by linkage between markers
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Fig. 2 Targeted-sequencing detects both coding and regulatory candidate variants in the four top-scoring genes a NRXN1 b HTR2A c CTTNBP2 and d REEP3.
Sequenced “Target regions” are shown as gray boxes above the red “–log10psingle” track displaying the association p-values for all detected variants and the
blue “AF ca/co ratio” track showing the ratio of OCD AF over control AF. “Candidate variants” are annotated as missense (red), synonymous (green),
untranslated (purple), DHS variants (blue), or unannotated (black). Lastly, the gene is shown as a horizontal blue line with exons (solid boxes) and arrows
indicating direction of transcription. The highest scoring isoform of NRXN1, NRXN1a-2, is shown in (a)
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(Kruskal–Wallis p= 5.6 × 10−15). This is consistent with previous
work showing that genes found through smaller candidate gene
studies replicate poorly11. It also suggests that, when a genome-wide
study of the disease of interest is not available, targeting genes
implicated in a model organism may be as effective as targeting genes
implicated in a comorbid, phenotypically similar human disorder.
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Fig. 3 Validated top candidate variants disrupt functional elements active in brain. a Frequencies of the top candidate variants show that most are rare
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The ﬁve genes most strongly implicated in canine CD and
murine-compulsive grooming (CDH2, CTNNA2, ATXN1, PGCP,
and Sapap3) have signiﬁcantly lower p-values than the other
603 sequenced genes (Wilcoxon unpaired, one-sided p= 2.6 × 10−4).
The difference becomes more signiﬁcant when only rare variants
are tested (Wilcoxon unpaired, one-sided p= 3.2 × 10−5) (Fig. 1c).
This is consistent with the hypothesis that severe disease-causing
variants, rare in humans due to negative selection, may persist at
higher frequencies in model organisms where selection is relaxed.
Applying the burden test across multiple genes with shared
biological functions, we identiﬁed gene sets with high-variant load
in OCD patients. We tested all 989 Gene Ontology (GO) sets that
are at least weakly enriched (enrichment p< 0.1) in our
608 sequenced genes (Supplementary Data 2) and found two
with high-variant burdens: “GO:0010942 positive regulation of
cell death” (uncorrected p= 3 × 10−4, corrected p< 0.03) and
“GO:0031334 positive regulation of protein complex assembly”
(uncorrected p= 7 × 10−4, corrected p< 0.06). Overlaying the
burden test results onto the GO network topology highlights
functional themes linking the enriched gene sets: regulation of
protein complex assembly and cytoskeleton organization; neuro-
nal migration; action potential; and cytoplasmic vesicle (Supple-
mentary Fig. 6).
Validation of candidate variants by genotyping. We genotyped
the top 67 candidate functional variants from the ﬁve signiﬁcant
genes, including 42 rare SNPs (AF< 0.01), in the pooled-
sequencing cohort (Fig. 3a). This yielded, after QC, individual
genotypes for 63 SNPs in 571 cases and 555 controls (98% of the
cohort; genotyping rate >0.94 for all SNPs). We see near perfect
correlation with the pooled sequencing for both allele frequencies
(Fig. 3b, c; OCD AF, Pearson’s ρ= 0.999, p= 2.7 × 10−89;
Control AF, Pearson’s ρ= 0.999, p= 2.5 × 10−89) and the AF
differences (Fig. 3d; OCD AF–control AF, Pearson’s ρ= 0.93,
p= 4.8 × 10−28).
We genotyped these 63 SNPs in an independent cohort of 727
cases and 1105 controls of European ancestry, and found strong
correlation with the ﬁrst genotyping cohort for both AF (Fig. 3e, f;
OCD AF, Pearson’s ρ= 0.999, p= 1.0 × 10−82; control AF,
Pearson’s ρ= 0.999, p= 1.8 × 10−94) and AF differences (Fig. 3g;
OCD AF–control AF, Pearson’s ρ= 0.4, p= 0.001). The risk allele
from the ﬁrst cohort is signiﬁcantly more common in cases in the
second cohort (Wilcoxon paired one-sided test for 63 SNPs,
p= 0.005). More speciﬁcally, of 54 SNPs that had a higher
frequency of the non-reference allele in cases in the ﬁrst cohort,
61% also had a higher frequency of the non-reference allele in
cases in the second cohort. The 33 SNPs that failed to validate in
either of the two cohorts had smaller allele-frequency differences
in the ﬁrst cohort (one-sided unpaired t-test p= 0.02).
In summary, the allele-frequency analysis described above
identiﬁed four genes: NRXN1, HTR2A, CTTNBP2, and REEP3.
LIPH is excluded because its association is likely slightly inﬂated
by LD and the genotyping in the second cohort did not reproduce
as clearly. To validate the associations, we employed distinct
strategies depending on whether the association was driven by
coding (NRXN1 and HTR2A) or regulatory variation (CTTNBP2
and REEP3).
Functional validation of regulatory variants using electrophoretic
mobility shift assay. For CTTNBP2 and REEP3, regulatory var-
iants give a far stronger burden signal than does testing for either
coding variants or all variants (Fig. 1b). Furthermore, the three
largest effect variants in the combined cohort (1298 OCD cases
and 1660 controls) alter enhancer elements in these two genes:
Table 2 Candidate regulatory variants
Chr:pos Ref Alt rsID Transcription factor EMSA OR GERP
CTTNBP2
chr7:117356081 T G None CTCF (GB, NB), RAD21 (NB, ESC) c Privatee b
chr7:117390966 T Del None CTCF (NB, CB), RAD21 (ESC) d Privatee b
chr7:117417559 A G rs75322384 b c 2.2 Conserved
chr7:117421141 C A None b d Privatee Conserved
chr7:117431202a C A None b b Privatee Conserved
chr7:117431704a C T None RAD21 (ESC) d Privatee Conserved
chr7:117431879a G A None b c Privatee b
chr7:117450810 C T rs34868515 SP1, YY1, EP300, JUND, TCF12, HDAC2, NANOG, BCL11A,
TEAD4 (all ESC)
b Private b
chr7:117456904 C T rs12706157 b c 1.06 b
chr7:117457141 G C rs13242822 b b 1.04 b
chr7:117468056 C T rs2067080 EP300 (NB), FOXP2 (NB), JUND (ESC) b 1.1 Conserved
chr7:117468334 T C rs2111209 EP300 (NB), FOXP2 (NB), JUND (ESC) b 1.04 b
REEP3
chr10:65307923 A G rs78109635 GATA2 (NB) c 1.01 Diverged
chr10:65332906 T C rs76646063 GATA3, GATA2, EP300 (all NB) c 3.7 Conserved
chr10:65387644 C G rs56311840 b b Privatee b
chr10:65387722 C Del None b d Privatee b
chr10:65388750 G A None SIN3A (NB), POLR2A (NB), REST (NB), USF1 (ESC), EP300
(NB)
b Privatee b
We identiﬁed twelve candidate regulatory SNPs in CTTNBP2, including: seven intronic SNPs with DHS signals in neural stem cells (SK-N-MC) or neuroblasts (SK-N-SH, BE2-C, SH-SY5Y, SK-N-SH-RA),
four of which also overlap TF-binding sites in the brain-derived cell lines; two intronic SNPs near the top DHS variants and potentially altering the same regulatory elements; and three coding SNPs that lie
within or near regulatory marks (Supplementary Fig. 7b). We also identiﬁed ﬁve candidate regulatory SNPs in or near REEP3, including: one intronic SNP (chr10:65307923) in a DHS and GATA2 TFBS
active in neuroblasts; one intronic SNP (chr10:65332906) that alters a DHS active in neural stem cells and GATA2, GATA3, and EP300 binding sites active in neuroblasts; three noncoding SNPs
(chr10:65387644, chr10:65387722, and chr10:65388750) that cluster ~3 kb upstream in a DHS active in multiple brain-related cells, including neuroblasts, and are seen only in OCD patients in our
pooled sequencing (Supplementary Fig. 7c).
aCoding; EMSA, electrophoretic mobility shift assay
bNo change
cStrong TF-DNA binding change
dWeak change; GB, glioblast; NB, neuroblast; ESC, embryonic stem cell; CB, cerebellum; “Transcription factor” column shows the TF bindings to the regions and brain/developmental cell types where the
signals are found. OR (odds ratio) column reports data in the combined set, unless noted with
eIndicating data from sequencing
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chr7:117358107 in CTTNBP2 (OR= 5.2) and chr10:65332906
(OR= 3.7) and chr10:65287863 (OR= 3.2) in REEP3 (Supple-
mentary Data 3). Using ENCODE and Roadmap Epigenomics
data, we identiﬁed 17 candidate SNPs in CTTNBP2 and REEP3,
likely to alter transcription factor-binding sites (TFBS) and/or
disrupt chromatin structure in brain-related cell types26, 29. All 17
alter enhancers or transcription associated loci active in either the
substantia nigra (SN), which relays signals from the striatum to
the thalamus, and/or the dorsolateral prefrontal cortex (DL-PFC),
which sends signals from the cortex to the striatum/thalamus
(Fig. 3h, i). Both regions act in the CSTC pathway implicated by
neurophysiological and genetic studies in OCD (Fig. 3j)30.
We functionally tested 17 candidate regulatory SNPs in REEP3
and CTTNBP2 (Table 2; Supplementary Fig. 7b). We introduced
each into a human neuroblastoma cell line (SK-N-BE(2)) and
assessed transcription factor binding using electrophoretic
mobility shift assays (EMSA). Both DHS SNPs in REEP3, three
of seven DHS SNPs in CTTNBP2, and one non-DHS variant in
CTTNBP2 clearly alter speciﬁc DNA-protein binding (Fig. 4a, b).
We see weak evidence of differential binding for one upstream
DHS SNP in REEP3, two DHS SNPs in CTTNBP2, and one non-
DHS SNP in CTTNBP2 (Supplementary Fig. 8).
The high rate of functional validation by EMSA demonstrates
that screening using both regulatory and evolutionary informa-
tion is remarkably effective in identifying strong candidate OCD-
risk variants. In total, eight of 12 tested DHS SNPs (67%) show
evidence of altered protein binding, despite testing a single cell
line at a single time point under standard-binding conditions
(Table 2). This includes two SNPs with high ORs in the full
genotyping data sets that strongly disrupt speciﬁc DNA-protein
binding (chr10:65332906 with OR= 3.7; chr7:117417559 with
OR= 2.2). Two of ﬁve non-DHS SNPs (40%) also show altered
binding, illustrating that DHS mark alone is a powerful but
imperfect predictor of regulatory function. Both of these SNPs
alter highly constrained elements (SiPhy score 8.7), whereas only
one of the three non-DHS SNPs is constrained. Although this is a
small data set, our results suggest that incorporating both DHS
and conservation may identify functional regulatory variants with
greater speciﬁcity, an observation consistent with previously
published research31.
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Fig. 4 Top genes validate in functional assays in context of known protein structure and in comparison to ExAC. EMSA of all 17 candidate regulatory
variants in a REEP3 and b CTTNBP2 reveals that six variants either decrease (black arrows) or increase (red) protein binding when the variant sequence
(MT) is compared with the reference allele (WT). The signal disappears when competing unlabeled probes (Cold+) are added, conﬁrming the speciﬁcity of
the DNA-protein binding. Raw images as well as EMSA results for experimental replicates and for other candidate regulatory variants that showed weak-
binding changes are shown in Supplementary Fig. 8. c All seven of the candidate missense variants in NRXN1, shown here as colored elements, alter the
extracellular postsynaptic-binding region of our top-scoring protein isoform NRXN1a-2 43, 59, 60. Of the six extracellular LNS (laminin, nectin, sex-hormone-
binding globulin) domains in the longer isoform NRXN1a, ﬁve with known protein structure are shown and labeled L2-L6. NRXN1a-2 includes four of these
domains (L2–L5; dashed ellipse). d The isoform-based test comparing OCD cases to ExAC ﬁnds NRXN1 as the top-scoring gene with genome-wide
signiﬁcance. The ExAC analysis score is deﬁned as the ratio of χ2 statistics (
Pn
i¼1
OiEið Þ2
Ei , where n= total number of isoforms, Oi= number of non-reference
alleles observed in isoform i, Ei= number of non-reference alleles expected from ExAC in isoform i) between OCD vs. ExAC comparison and control vs.
ExAC comparison
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Validation of coding variants using ExAC. In contrast to the
regulatory-variant burden found in CTTNBP2 and REEP3,
NRXN1 and HTR2A showed signiﬁcant PolyStrat signals when
only coding variants are considered. Of 12 candidate coding SNPs
in NRXN1, seven are missense (Table 3). Four of these are SNPs
private to OCD cases, and the other three are rare (AF in controls
0.0009–0.0036). All seven change amino acids in laminin G or
EGF-like domains important for postsynaptic binding, potentially
affecting the involvement of NRXN1 in synapse formation and
maintenance (Fig. 4c). Of the three candidate coding SNPs in
HTR2A, two (one missense and one synonymous) are in the last
coding exon, and one (missense) is the cytoplasmic domain with
a PDZ-binding motif, potentially affecting binding afﬁnity or
speciﬁcity32.
We sought to improve our statistical power by combining our
pooled-sequencing data with publicly available ExAC data33.
Using only our data, the associations of CTTNBP2, REEP3,
NRXN1, and HTR2A with OCD are experiment-wide signiﬁcant,
but do not reach the genome-wide signiﬁcance threshold
p< 2.5 × 10−6 (~20,000 human genes), with the strongest associa-
tion, to NRXN1, at p= 5.1 × 10−5 (cohort 1 and 2; Fisher’s
combined p). For the two genes with a burden of coding variants
(NRXN1 and HTR2A), we used ExAC to assess variant burden in
OCD cases compared with 33,370 non-Finnish Europeans. Such a
comparison was not possible for CTTNBP2 and REEP3, for which
associated variants are predominantly noncoding and thus not
assayed in ExAC.
To assess the signiﬁcance of the variant enrichment in each
gene, we used an isoform-based test that incorporates a within-
gene comparison to assess signiﬁcance, effectively controlling for
inﬂation due to the extremely large size of the ExAC cohort34
(Supplementary Methods). Of 542 genes with more than one
isoform, we saw no signiﬁcant difference between our control
data and ExAC for over 90% (493 genes had corrected p> 0.05).
Focusing on the subset of 66 genes with nominally signiﬁcant
PolyStrat scores, NRXN1 had the largest difference between cases
and ExAC (χ2 = 82.3, df= 16, uncorrected p= 6.37 × 10−11;
corrected p= 1.27 × 10−6) and no difference between controls
and ExAC (χ2= 10.5, df= 16, uncorrected p= 0.84) (Fig. 4d). No
previous ﬁndings in OCD genetics have reached this level of
signiﬁcance despite >100 candidate gene studies35, a dozen
linkage studies30, and two GWAS2, 3. HTR2A, while enriched for
coding variants, had only two SNPs in cases, providing
insufﬁcient information for the isoform test.
The signiﬁcant association of NRXN1 reﬂects an exceptional
burden of variants in one of its 17 Ensembl isoforms. NRXN1a-2,
which contains all 12 candidate coding SNPs, had the largest
deviation between observed and expected variant counts, with a
residual at least 1.4× higher than any other isoform (NRXN1a-2
= 22.3, NRXN1-001= 16.3; median= 5.15). After adjusting for
the residuals from the “null” control data and ExAC comparison,
the NRXN1a-2 residual is still 1.3× higher (OCD residual/control
residual NRXN1a-2= 5.34, NRXN1-014 = 4.04).
Discussion
By analyzing sequencing data for 608 OCD candidate genes, then
prioritizing variants according to functional and conservation
annotations, we identiﬁed four genes with a reproducible variant
burden in OCD cases. Two genes, NRXN1 and HTR2A (Table 3),
have a burden of coding variants, and the other two, CTTNBP2
and REEP3 (Table 2), have a burden of conserved regulatory
variants. Notably, all four act in neural pathways linked to OCD,
including serotonin and glutamate signaling, synaptic con-
nectivity, and the CSTC circuit6, offering new insight into the
biological basis of compulsive behavior (Fig. 5).
We used three independent approaches to validate our ﬁnd-
ings: (1) For the top candidate SNPs, allele-frequency differences
from sequencing data were conﬁrmed by genotyping of both the
original cohort (Fig. 3d) and a larger, independent cohort
(Fig. 3g). (2) For the two genes with a burden of coding variants
(NRXN1 and HTR2A), comparison of our data to 33,370
population-matched controls from ExAC33 revealed genome-
Table 3 Coding variants in NRXN1 and HTR2A
Chr:pos Ref Alt rsID OCD allele
freq.
Ctrl allele
freq.
ExAC allele
freq.
Amino acid
change
Candidate variant from
sequencing
NRXN1
chr2:50149133 C T rs113380721 0.0019 0.0030 0.0033 Syn No
chr2:50149214 A G rs112536447 0.0001 0.0010 0.0003 Syn No
chr2:50280604 T C rs79970751 0.0088 0.0070 0.0058 Syn No
chr2:50463984 G A rs147580960 0.0009 0.0006 0 Syn Yes
chr2:50464065 C T rs80094872 0.0009 0.0003 0a Syn Yes
chr2:50699479 G A rs75275592 0.0009 0.0013 0.0010 Syn No
chr2:50723068 G A rs56402642 0.0034 0.0001 0.0018 Syn Yes
chr2:50724642 A G none 0.0009 0 0 I>T Yes
chr2:50724745 G T rs201818223 0.0017 0.0009 0.0011 L>M Yes
chr2:50733745 G C rs147984237 0.0017 0 1.5 × 10−5 Syn Yes
chr2:50765412 G T rs56086732 0.0089 0.0028 0.0056 L>I Yes
chr2:50765589 T C rs200074974 0.0016 0 0.0011 I>V Yes
chr2:50779791 C T None 0.0008 0 0a A>T Yes
chr2:50779943 T C None 0.0009 0 0a N>S Yes
chr2:50847195 G A rs78540316 0.0077 0.0036 0.0043 P>S Yes
chr2:50850686 G A rs2303298 0.0107 0.0013 0.0038 Syn Yes
HTR2A
chr13:47409048 G A rs6308 0.0036 0.0012 0.0023 A>V Yes
chr13:47409701 G A rs141413930 0.0020 0.0012 0.0026a Syn Yes
chr13:47409149 T A rs35224115 0.0019 0.0047 0.0044 Syn No
chr13:47466622 G A rs6305 0.0386 0.0225 0.027b Syn Yes
ExAC allele freq. shown for NFE population
aExcluded from ExAC analysis because of low-conﬁdence call from pooled sequencing
bExcluded from ExAC analysis because of frequency >0.01
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wide-signiﬁcant association of NRXN1 with OCD. (3) For the two
genes with the burden of regulatory variants (REEP3 and
CTTNBP2), more than one-third of candidate SNPs altered
protein/DNA binding in a neuroblastoma cell line (Fig. 4a).
Comparison of our approach to existing methods illustrates its
unique advantages, and offers a deeper understanding of how its
two key features—targeted sequencing, and incorporation of
functional and conservation metrics—permit identiﬁcation of
signiﬁcantly associated genes using a cohort smaller even than
those that have previously failed to yield signiﬁcant results.
Targeted sequencing captures both coding and regulatory
variants, and both common and rare variants, at a fraction of the
cost of whole-genome sequencing (WGS). For the modest-size
cohort in this study, WGS would cost ~$2.5M, 40-fold more than
our pooled-sequencing approach. Even without pooling, our
targeted-sequencing costs fourfold less than WGS. Whole-exome
sequencing would cost approximately the same as targeted
sequencing, but misses the regulatory variants explaining most
polygenic trait heritability21. By using existing information on
OCD and related diseases to prioritize a large set of genes, then
performing targeted sequencing of functional elements, our
approach enhances causal-variant detection and thus statistical
power, although it misses OCD-associated genes not included as
candidates, and potential distant regulatory elements.
The capacity to detect associations to rare variants is especially
critical for study of diseases that, like OCD, may reduce ﬁtness, as
negative selection limits inheritance of deleterious variants36.
Genotype array data sets, and even imputed data sets, miss many
rare variants. In our data set, 80% of variants driving signiﬁcant
associations have allele frequencies <0.05; one of the densest
genotyping arrays available, the Illumina Inﬁnium Omni5 (4.3M
markers) contains only half of these variants (Supplementary
Data 1)2, 3. In addition, 60% of our variants have allele fre-
quencies <0.01, and would be missed even through imputation
with 1000 Genomes and UK10K37.
Our new analytical method, Poly Strat, analyzes targeted-
sequencing data capturing all variants, and leverages public
evolutionary and regulatory data to increase power. PolyStrat ﬁrst
ﬁlters out variants that are less likely to be functional, then per-
forms gene-burden tests. In contrast to gene-based approaches
focusing on ultra-rare, protein-damaging variants, PolyStrat
considers variants of diverse frequencies, gaining power to
identify genes with excess variants in cases.
PolyStrat is particularly advantageous when applied to studies
with smaller cohorts. By testing for association at the gene level, it
requires statistical correction only for the ~20,000 genes in the
genome. It increases power further by using targeted-sequencing
data to capture nearly all variation, including variants with higher
allele frequencies and/or larger effect sizes, in regions that are
coding or evolutionarily constrained, and enriching for causal
variants by removing ~33% of variants unlikely to be func-
tional38. PolyStrat tests ~82 times more functional variants than
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), which focu-
ses on protein-damaging variants (27,626 vs. 335 in our data).
Our PolyStrat results are consistent with expectations from
simulations, which suggest that 200–700 cases should yield 90%
power to detect associated genes with allele frequencies and effect
sizes similar to our four genes39. Speciﬁcally, we would achieve
90% power to detect associations to NRXN1 (combined AF=
0.022, OR= 2.4) with ~600 cases, to HTR2A (combined AF=
0.03, OR= 1.56) with ~700 cases; to REEP3 (combined AF= 0.04,
OR= 2.11) with ~200 cases, and to rare (AF< 0.01) variants in
CTTNBP2 (combined AF= 0.003, OR= 4.7) with ~500 cases.
Previous research on the four genes identiﬁed by PolyStrat
revealed that all are expressed in the striatum, a brain region
linked to OCD (http://human.brain-map.org/). All four genes are
involved in pathways relevant to brain function, and harbor
variants that could alter OCD risk (Table 4).
NRXN1 encodes the synapse cell-adhesion protein neurexin 1α,
a component of cortico-striatal neural pathway40, 41 implicated in
ASD and other psychiatric diseases42, and functionally related to
genes associated with OCD (CDH9/CDH10)3, 8, 9 and canine CD8,
9 (CDH2) (Fig. 5). NRXN1 isoforms are implicated in distinct
neuropsychiatric disorders. The non-synonymous variants in the
NRXN1a-2 isoform (Fig. 4c) may alter synaptic function by dis-
rupting cellular localization or interactions with binding partners,
including neurexophilins43. The ﬁve synonymous candidate var-
iants in likely regulatory elements may affect protein folding by
disrupting post-transcriptional regulation, seen in other neu-
ropsychiatic disorders44.
The synaptic plasticity gene REEP3, also implicated in ASD45,
encodes a protein that shapes tubular endoplasmic reticulum
membranes found in highly polarized cells, including neurons46.
The two EMSA-validated REEP3 variants change regulatory ele-
ments active in the cortico-striatal neural pathway (Fig. 3h) and
bound by multiple TFs (Table 2) including GATA2, which may
be required to actuate inhibitory GABAergic neurons47. Thus,
variants disrupting GATA2 binding could change the balance
between excitatory and inhibitory neurons in the CSTC circuit
(Fig. 3j)30.
CTTNBP2 regulates postsynaptic excitatory synapse formation.
All four EMSA - conﬁrmed variants in CTTNBP2 alter epigenetic
marks active in the key structures of the cortico-striatal neural
pathway48 (Table 2; Fig. 3h), potentially affecting the expression
of this critical gene. CTTNBP2 proteins interact with both pro-
teins encoded by STRN (striatin), which approached experiment-
wide signiﬁcance in this study (uncorrected p= 0.0016, corrected
p< 0.1; Fig. 1b) and the canine CD gene CDH2 (Fig. 5).
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Fig. 5 All four top candidate genes function at the synapse and interact with
proteins implicated in OCD by previous studies in the three species.
Human, dog, and mouse are marked with superscripts h, d, and m,
respectively. Genes identiﬁed in this study are shown in red. Solid lines
indicate direct interactions, and dashed lines indicate indirect interactions
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HTR2A encodes a G-protein-coupled serotonin receptor
expressed throughout the central nervous system, including in the
prefrontal cortex, and has been implicated in ASD and OCD35. A
related serotonin-receptor cluster (HTR3C/HTR3D/HTR3E) is
associated with severe canine CD49(Fig. 5). The three
coding variants found in HTR2A may alter its binding afﬁnity
(Table 3)32, and one of the three, a rare missense variant (rs6308;
AF= 0.004 in 1000G CEU population) is perfectly linked (D′= 1;
http://raggr.usc.edu) to a common variant (rs6314) associated
with response to SSRIs50.
Taken together, our top four associated genes and our pathway
analysis implicate three classes of neuronal functions in OCD, as
described below.
First, synaptic cell-adhesion molecules help establish and
maintain contact between the presynaptic and postsynaptic
membrane, and are critical for synapse development and neural
plasticity. NRXN1 encodes a cell-adhesion molecule pre-
dominantly expressed in the brain, and CTTNBP2 regulates
cortactin, another such molecule, echoing earlier ﬁndings linking
cell-adhesion genes to compulsive disorders in dogs (CDH2 and
CTNNA2), mice (Slitrk5), and humans (DLGAP1, PTPRD and
CDH9/CDH10)2, 3, 8, 51 (Fig. 5). In our pathway analysis, “reg-
ulation of protein complex assembly” and “cytoskeleton organi-
zation” were enriched for variants in OCD patients.
Second, OCD may result from an imbalance of excitatory
glutamate and inhibitory GABAergic neuron differentiation30
(Fig. 3j), a process that involves both NRXN152 and REEP353
(Table 4), as well as PTPRD, a top OCD GWAS candidate3. We
also ﬁnd an overall burden of variants in genes regulating cell
death and apoptosis (Supplementary Data 2) and in telencephalic
tangential migration, a neuronal migration event which forms
connections between the key structures of CSTC circuit54.
Third, SSRIs are the most effective available OCD treatment,
suggesting a role for serotonergic pathways in disease. HTR2A
encodes a serotonin receptor, and allelic variation in HTR2A
alters response to SSRIs (Table 4)50. In addition, both REEP3 and
CACNA1C, which score high in this study (Fig. 1), also
signiﬁcantly associate with schizophrenia and act in calcium
signaling, a downstream pathway of HTR2A55–57. Meta-analysis
of >100 OCD genetic association studies found strong association
to both HTR2A and the serotonin transporter gene SLC6A435. In
dogs, a serotonin-receptor locus is associated with severe CD49.
Our ﬁndings suggest broad principles that could guide studies
of other polygenic diseases. We discovered that genes associated
in selectively bred model organisms are more likely to contain
rare, highly penetrant variants. The ﬁve genes we found to be
most strongly associated with compulsive behaviors in dog and
mouse (CDH2, CTNNA2, ATXN1, PGCP, and Sapap3) were
signiﬁcantly more enriched for rare variants in human patients
than the other 603 genes targeted, although they did not indivi-
dually achieve signiﬁcance (Fig. 1c). We propose that the
enrichment of rare variants in humans reﬂects natural selective
forces limiting the prevalence of severe disease-causing variants.
Such forces are less powerful in selectively bred animal popula-
tions. Because risk variants identiﬁed through animal models are
anticipated to be rare in humans, replication will require either
family-based studies, or cohorts of magnitude not currently
available.
We also ﬁnd that the ratio of coding to regulatory variants is
positively correlated with a gene’s developmental importance.
Although single-gene p-values from PolyStrat tests are positively
correlated across variant categories, as is expected given overlaps
between different variant categories (Fig. 1a; Supplementary
Fig. 9), this pattern breaks down for our four signiﬁcantly
associated genes. NRXN1 and HTR2A, which have burdens of
coding variants, score poorly on regulatory-variant tests;
CTTNBP2 and REEP3, which have burdens of regulatory variants,
score poorly in coding-variant tests (Fig. 1b). This is consistent
with the ExAC study showing that genes critical to viability or
development do not tolerate major coding changes33. In that
study, the authors infer that CTTNBP2 and REEP3 would be
intolerant of homozygous loss of function variants (pRec=
0.99999015 and pRec= 0.953842585, respectively), whereas
HTR2A (pRec= 0.225555783) and, most notably, NRXN1 (pRec
Table 4 Summary of top genes
NRXN1 REEP3 CTTNBP2 HTR2A
Gene product/
brain relevance
Synaptic cell-adhesion protein/
synapse functioning and
development in the cortical-
striatal pathway40, 41
Microtubule-binding protein/
possible role in synaptic
plasticity, calcium signaling,
shaping tubular ER membranes
in neurons46
Cortical actin (cortactin)-
binding protein/synaptic
maintenance48
G-protein-coupled serotonin
receptor/cortical neuron
excitation63
Disease relevance Neurodevelopmental disorders
incl. ASD42, 64
ASD45 Interacts with CDH2,
implicated in canine
CD8, 9, 65
ASD, OCD35, canine CD (5-HT3
receptors)49
Reason for
inclusion as
candidatea
(1) Model (mouse) organism
gene; (2) ASD gene
(2) ASD gene (1) Model (mouse)
organism gene
(1) Model (dog) organism gene;
(2) human candidate—SSRI
target
Type of burden
identiﬁed
Coding variants—missense
variants over-represented to
one isoform, NRXN1a-2
Regulatory variants Regulatory variants Coding variants—missense
variant in perfect linkage to a
common variant rs6314
associated with response to
SSRIs50
Validation of
variants identiﬁed
in present study
By comparison to ExAC—
genome-wide-signiﬁcant
association
By EMSA—disrupt regulatory
elements bound by various TF,
including GATA2
By EMSA—alter epigenetic
marks active in the cortico-
striatal pathway
By genotyping independent
cohort; too few polymorphic
sites for validation with ExAC
Hypothesized
impact of variants
identiﬁed
Inaccurate cellular localization
of NRXN1, or altered binding
competition to its partner,
modifying synaptic adhesion43
REEP3 expression in GABA
neurons inhibited by variants
that reduce GATA2 binding47,
leading to excitatory/inhibitory
imbalance in CSTC circuit30
Altered CTTNBP2
expression in cortical-
striatal circuit in brain66
Altered binding afﬁnity of
HTR2A, changing the activation
of downstream calcium signaling
in neurons32
aFor explanation of each category, see “Results” section
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= 5.13 × 10−5) would be far more tolerant. Our ﬁnding of
enrichment for regulatory variants in CTTNBP2 and REEP3
suggests that these genes may tolerate variants with more subtle
functional impacts, such as expression differences in speciﬁc cell
types or developmental stages.
Technological advances in high-throughput sequencing bring
increased focus on identifying causal genetic variants as a ﬁrst
step toward targeted disease therapies58. However, existing
approaches have notable limitations. WGS is prohibitively
expensive in large cohorts, whereas cost-saving whole-exome
sequencing does not capture the regulatory variants underlying
complex diseases21. Leveraging existing genomic resources can
increase power to ﬁnd causal variants through meta-analysis and
imputation, but these resources are heavily biased towards a few
populations. Without new approaches, advances in precision
medicine will predominantly beneﬁt those of European descent.
Here, we describe an approach that combines prior ﬁndings,
targeted sequencing, and a new analytic method to efﬁciently
identify genes and individual variants associated with complex
disease risk. In a modest-size cohort of OCD cases and controls
we ﬁnd associations driven by both coding and regulatory var-
iants, highlighting new potential therapeutic targets. Our method
holds promise for elucidating the biological basis of complex
disease, and for extending the power of precision medicine to
previously excluded populations.
Methods
Study design. We designed and carried out the study in two phases. In the ﬁrst,
discovery phase, we performed targeted sequencing of 592 individuals with DSM-
IV OCD and 560 controls of European ancestry, and tested association for OCD at
single variant-level, gene-level, and pathway-level. In the second, validation phase,
we employed three distinct analyses. (1) We genotyped both the original cohort
and a second, independent cohort containing 1834 DNA samples (729 DSM-IV
OCD cases and 1105 controls) of European ancestry, including a total of 2986
individuals (1321 OCD cases and 1665 controls) to conﬁrm the observed allele
frequencies in the discovery phase. (2) We compared our sequencing data with
33,370 population-matched controls from ExAC to conﬁrm the gene-based burden
of coding variants as well as allele frequencies. (3) We performed EMSA to test
whether our candidate variants have regulatory function. Uses of biospecimens in
this study were reviewed and approved by either the Broad's Ofﬁce of Research
Subject Protection, or the Partners HealthCare Human Research Committee.
Informed consent was obtained from all subjects included in our study.
Targeted regions. We targeted 82,723 evolutionarily constrained regions in and
around 608 genes, which included all regions within 1 kb of the start and end of
each of 608 targeted genes with SiPhy evolutionarily constraint score >7, as well as
all exons22. For the intergenic regions upstream and downstream of each gene, we
used constraint score thresholds that became more stringent with distance from the
gene.
Pooled sequencing and variant annotation. Groups of 16 individuals were
pooled together into 37 case pools and 35 control pools and bar-coded. Targeted-
genomic regions were captured using a custom NimbleGen hybrid capture array
and sequenced by Illumina GAII or Illumina HiSeq2000. Sequencing reads were
aligned and processed by Picard analysis pipeline (http://broadinstitute.github.io/
picard/). Variants and AFs were called using Syzygy17 and SNVer23. We used
ANNOVAR25 to annotate variants for RefSeq genes (hg19), GERP scores,
ENCODE DHS cluster, and 1000 G data.
Genotyping. SNP genotyping was performed using the Sequenom MassARRAY
iPLEX platform. The resulting data were analyzed using PLINK1.9 (www.
cog-genomics.org/plink2).
EMSA. For each allele of the tested variants, pairs of 5′-biotinylated oligonucleo-
tides were obtained from IDT Inc. (Supplementary Data 4). Equal volumes of
forward and reverse oligonucleotides (1 pmol/µl) were mixed and heated at 95°C
for 5 min and then cooled to room temperature. Annealed probes were incubated
at room temperature for 30 min with SK-N-BE(2) nuclear extract (Active Motif).
The remaining steps followed the LightShift Chemiluminescent EMSA Kit protocol
(Thermo Scientiﬁc).
Statistical analysis. For gene-association/pathway-association, we used the sum of
the differences of non-reference allele rates between cases and controls per gene as
test statistic, and calculated the probability of observing a test statistic by chance
from 10,000 permutations. Multiple testing was empirically corrected using “minP”
procedure. See Supplementary Methods for details.
Code availability. The code used in this study was obtained from R package
Rplinkseq and PLINK1.9.
Data availability. All data presented in this study are accessible at: https://data.
broadinstitute.org/OCD_NatureCommunications2017/.
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